| Budget Amount *help |
¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2017: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2016: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2015: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
|---|
| Outline of Final Research Achievements |
To improve the treatment results of brachytherapy for thick oral cancer, we started this study of induction oral-chemotherapy using TS-1 followed by low-dose-rate brachytherapy. The treatment protocol consisted of 1 or 2 cycles of the TS-1 regimen (80-120 mg/day) according to a 2-weeks-on/1-week-off schedule followed by brachytherapy using low-dose-rate Ir-192 pins or Au-198 grains. The primary endpoint was the rate of complications, and the secondary endpoints were the local control rate and the rate of secondary cervical lymph node metastasis.
Between August 2015 and June 2017, 16 patients were enrolled. Although a few patients suffered from renal dysfunction, hepatic dysfunction, severe fatigue, or dermatitis by TS-1, the incidence of complications due to brachytherapy did not increase. The local control rate was the same as that in past reports. However, the rate of cervical lymph node metastasis was correlated with the number of cycles of the TS-1 regimen.
|
